arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BRISTOL MYERS SQUIBB CO

BMY
$63.41 ▼ -0.79 (-1.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
68
Health
Good
Neutral
auto_awesome

Analytical Summary

BRISTOL MYERS SQUIBB CO shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $129.0B
Dividend Yield 3.93%
Revenue Growth -0.2% ↘
Op. Margin —
ROIC —
FCF / Share $6.32 ↘
Trailing P/E 18.3x
Price / Book 7.0x
FCF Yield 10.0%
Debt / Equity 2.55
info Valuation on last close. End-of-day price, Nov 5, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$48.19B
— -0.2% —
Net Income Profit after all expenses
$7.05B
↑ +178.8% —
FCF / Share Free cash flow per share
$6.32
↓ -8.2% —
Long-Term Debt Long-term obligations
$44.83B
↓ -9.3% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↓
82
Returns ↑
95
Financial Health ↑
10
Cash Quality ↓
84

Dividend History

Dividend / share · sourced from SEC filings
$2.49 Latest / share
+2.9% YoY
+5.0% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 76 quarters